title: Radiotherapy in laryngeal carcinoma: can a panel of 13 markers predict response?
abstract: OBJECTIVE
  To find biomarkers associated with response to radiotherapy in laryngeal cancer that can be used together with clinical parameters to improve outcome prediction.
  
  
  METHODS
  In this study, 26 patients irradiated for laryngeal carcinomas with a local recurrence within two years (cases) and 33 patients without recurrence (controls) were included. All pretreatment biopsies were arrayed onto a tissue array. Immunohistochemistry was performed for 13 biomarkers that were selected from the literature as potential predictors for radioresponse in head and neck (HN) cancer: Bcl-2, Bcl-xL, p16, p21, p27, p53, cyclin D1, HIF-1alpha, CA9, COX-2, EGFR, ki-67, and pRB.
  
  
  RESULTS
  Univariate logistic regression models showed borderline statistically significant increased relative risks, with positivity for CA9, COX-2, and p53. Goeman's global testing revealed an overall association between outcome and the 13 markers together with clinical variables. The most important markers were CA9 and COX-2.
  
  
  CONCLUSIONS
  In laryngeal carcinoma, hypoxia and COX-2 overexpression provide a stronger contribution to an increased risk of local recurrence after radiotherapy compared with the well-known candidate markers p53, Bcl-2, and cyclin D1. However, no robust expression profile for the prediction of radioresistance was found.
authors.affiliation: Department of Head and Neck Oncology and Surgery, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
authors.forename: Maarten A M
authors.initials: MA
authors.lastname: Wildeman
authors.forename: Johan H
authors.initials: JH
authors.lastname: Gibcus
authors.forename: Michael
authors.initials: M
authors.lastname: Hauptmann
authors.forename: Adrian C
authors.initials: AC
authors.lastname: Begg
authors.forename: Marie Louise F
authors.initials: ML
authors.lastname: van Velthuysen
authors.forename: Frank J
authors.initials: FJ
authors.lastname: Hoebers
authors.forename: Mirjam F
authors.initials: MF
authors.lastname: Mastik
authors.forename: Ed
authors.initials: E
authors.lastname: Schuuring
authors.forename: Jacqueline E
authors.initials: JE
authors.lastname: van der Wal
authors.forename: Michiel W M
authors.initials: MW
authors.lastname: van den Brekel
mesh_terms: D000368:Aged; D000951:Antigens, Neoplasm / Q000032:analysis; D014408:Biomarkers, Tumor / Q000032:analysis*; D000071231:Carbonic Anhydrase IX; D002256:Carbonic Anhydrases / Q000032:analysis; D016022:Case-Control Studies; D051546:Cyclooxygenase 2 / Q000032:analysis; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D007822:Laryngeal Neoplasms / Q000532:radiotherapy*; D016015:Logistic Models; D008297:Male; D009364:Neoplasm Recurrence, Local; D011237:Predictive Value of Tests
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; C089226:CA9 protein, human; D000071231:Carbonic Anhydrase IX; D002256:Carbonic Anhydrases